ReviewFrontiers in pediatrics2021
Similarities and Differences Between COVID-19-Related Multisystem Inflammatory Syndrome in Children and Kawasaki Disease.
Review in Frontiers in pediatrics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Global Myocardial Strain in Multisystem Inflammatory Syndrome in Children, Kawasaki Disease, and Healthy Children: A Network Meta-Analysis.Frontiers in pediatrics · 2022Pooled it
- Pediatric health: mechanistic insights into inflammatory diseases and emerging therapeutic pathway-targeted approaches.Translational pediatrics · 2026Review
- MIS-C: Diagnosis, Management, and Outcomes.Open forum infectious diseases · 2026Review
- Observational
- The clinical manifestation and diagnostic features of Kawasaki-like phenotypes in pediatric multisystem inflammatory syndrome: a comparative retrospective study in Ukraine.Frontiers in pediatrics · 2025Article
- Acute Abdomen as a Clinical Presentation of COVID-19-Associated Multisystem Inflammatory Syndrome in Children.Case reports in surgery · 2024Article
- Clinical and Laboratory Characteristics of Kawasaki Disease and COVID-19-Related Multisystem Inflammatory Syndrome in Children.Journal of Korean medical science · 2023Article
- Multisystem inflammatory syndrome in adults: Comparison with other inflammatory conditions during the Covid-19 pandemic.Respiratory medicine · 2023Article
- Coronavirus disease 2019-related Kawasaki syndrome: a case report.Journal of medical case reports · 2022Article
- Pediatric cardiothoracic vasculitis: multimodality imaging review.Pediatric radiology · 2022Review
- Multisystem inflammatory syndrome with erythema multiforme-like rash in an adult after mRNA COVID-19 vaccination.Annales de dermatologie et de venereologie · 2022Article
- Infliximab treatment for refractory COVID-19-associated multisystem inflammatory syndrome in a Japanese child.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 2022Article
- Distinguishing immune activation and inflammatory signatures of multisystem inflammatory syndrome in children (MIS-C) versus hemophagocytic lymphohistiocytosis (HLH).The Journal of allergy and clinical immunology · 2022Article
- Longitudinal Outcomes and Monitoring of Patients With Multisystem Inflammatory Syndrome in Children.Frontiers in pediatrics · 2022Review
- Case Report: Successful Treatment of a Child With COVID-19 Reinfection-Induced Fulminant Myocarditis by Cytokine-AdsorbingFrontiers in pediatrics · 2022Article
- Kawasaki disease in Malaysia: Biochemical profile, characterization, diagnosis and treatment.Frontiers in pediatrics · 2022Article
- Global Research Trends in Pediatric COVID-19: A Bibliometric Analysis.Frontiers in public health · 2022Article
- Clinical characteristics of Kawasaki disease in adolescents.The Journal of international medical research · 2021Article
- Unraveling the mechanisms of IVIG immunotherapy in MIS-C.Cell reports. Medicine · 2021Article
- Kawasaki Disease Versus Multisystem Inflammatory Syndrome in Children: Exploring the Complexities of Pediatric Cardiac Inflammatory Disorders.Sage open pediatricsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In December 2019, the first case of coronavirus disease (COVID-19) was first reported in Wuhan, China. As of March 2021, there were more than 120 million confirmed cases of COVID-19 and 2.7 million deaths. The COVID-19 mortality rate in adults is around 1-5%, and only a small proportion of children requires hospitalization and intensive care. Recently, an increasing number of COVID-19 cases in children have been associated with a new multisystem inflammatory syndrome. Its clinical features and laboratory characteristics are similar to those of Kawasaki disease (KD), KD shock syndrome, and toxic shock syndrome. However, this new disorder has some distinct clinical features and laboratory characteristics. This condition, also known as multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19, has been observed mostly in Europe and the United States. This emerging phenomenon has raised the question of whether this disorder is KD triggered by SARS-CoV-2 or a syndrome characterized by multisystem inflammation that mimics KD. This narrative review is to discuss the differences between MIS-C and KD with the aim of increasing pediatricians' awareness of this new condition and guide them in the process of differential diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.